Lopinavir impairs protein synthesis and induces eEF2 phosphorylation via the activation of AMP-activated protein kinase

Journal of Cellular Biochemistry

Volumn 105, Issue 3, 2008, Pages 814-823

  Hong Brown, Ly Q ^a   Brown, C Randell ^a   Huber, Danuta S ^a   Lang, Charles H ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

AMPK; eEF2K; HIV anti retroviral drugs

Indexed keywords

ELONGATION FACTOR 2; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LOPINAVIR; ROTTLERIN;

ANIMAL CELL; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVATION; GENE REPRESSION; IN VITRO STUDY; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA TRANSLATION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELLS, CULTURED; ELONGATION FACTOR 2 KINASE; HIV PROTEASE INHIBITORS; MICE; PEPTIDE ELONGATION FACTOR 2; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PYRIMIDINONES;

EID: 54849427710     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21882     Document Type: Article

References (45)

1. Atherton PJ, Babraj J, Smith K, Singh J, Rennie MJ, Wackerhage H. 2005. Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation. FASEB J 19:786-788.
2. Ben-Romano R, Rudich A, Etzion S, Potashnik R, Kagan E, Greenbaum U, Bashan N. 2006. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: Differential protective effect of antioxidant agents. Antivir Ther 11:1051-1060.
3. Browne GJ, Proud CG. 2002. Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem 269:5360-5368.
4. Browne GJ, Finn SG, Proud CG. 2004. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 279:12220-12231.
5. Carroll M, Warren O, Fan X, Sossin WS. 2004. 5-HT stimulates eEF2 dephosphorylation in a rapamycin-sensitive manner in Aplysia neurites. J Neurochem 90:1464-1476.
6. Crozier SJ, Vary TC, Kimball SR, Jefferson LS. 2005. Cellular energy status modulates translational control mechanisms in ischemic-reperfused rat hearts. Am J Physiol Heart Circ Physiol 289:H1242-H1250.
7. Dorovkov MV, Pavur KS, Petrov AN, Ryazanov AG. 2002. Regulation of elongation factor-2 kinase by pH. Biochemistry 41:13444-13450.
8. Ergun-Longmire B, Lin-Su K, Dunn AM, Chan L, Ham K, Sison C, Stavola J, Vogiatzi MG. 2006. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr Pract 12:514-521.
9. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F. 1994. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199:93-98.
10. Guiard-Schmid JB, Poirier JM, Meynard JL, Bonnard P, Gbadoe AH, Amiel C, Calligaris F, Abraham B, Pialoux G, Girard PM, Jaillon P, Rozenbaum W. 2003. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 47:986-990.
11. Gutierrez F, Padilla S, Navarro A, Masia M, Hernandez I, Ramos J, Esteban A, Martin-Hidalgo A. 2003. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 33:594-600.
12. Hong-Brown LQ, Brown CR, Lang CH. 2004. Indinavir impairs protein synthesis and phosphorylations of MAPKs in mouse C2C12 myocytes. Am J Physiol Cell Physiol 287:C1482-C1492.
13. Hong-Brown LQ, Brown CR, Lang CH. 2005. HIV antiretroviral agents inhibit protein synthesis and decrease ribosomal protein S6 and 4EBP1 phosphorylation in C2C12 myocytes. AIDS Res Hum Retroviruses 21:854-862.
14. Hong-Brown LQ, Brown CR, Huber DS, Lang CH. 2007. Alcohol regulates eukaryotic elongation factor 2 phosphorylation via an AMP-activated protein kinase-dependent mechanism in C2C12 skeletal myocytes. J Biol Chem 282:3702-3712.
15. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoinne A, Hue L, Proud C, Rider M. 2002. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12:1419-1423.
16. Horman S, Beauloye C, Vertommen D, Vanoverschelde JL, Hue L, Rider MH. 2003. Myocardial ischemia and increased heart work modulate the phosphorylation state of eukaryotic elongation factor-2. J Biol Chem 278:41970-41976.
17. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR, Sun E. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 47:350-359.
18. Inamura N, Nawa H, Takei N. 2005. Enhancement of translation elongation in neurons by brain-derived neurotrophic factor: Implications for mammalian target of rapamycin signaling. J Neurochem 95:1438-1445.
19. Jain RG, Lenhard JM. 2002. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 277:19247-19250.
20. Janneh O, Hoggard PG, Tjia JF, Jones SP, Khoo SH, Maher B, Back DJ, Pirmohamed M. 2003. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther 8:417-426.
21. Mangili A, Murman DH, Zampini AM, Wanke CA. 2006. Nutrition and HIV infection: Review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis 42:836-842.
22. McLeod LE, Proud CG. 2002. ATP depletion increases phosphorylation of elongation factor eEF2 in adult cardiomyocytes independently of inhibition of mTOR signalling. FEBS Lett 531:448-452.
23. Mitsui K, Brady M, Palfrey HC, Nairn AC. 1993. Purification and characterization of calmodulin-dependent protein kinase III from rabbit reticulocytes and rat pancreas. J Biol Chem 268:13422-13433.
24. Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Perez S, Zapata A, Gonzalez-Garcia JJ, Pena JM, Vazquez JJ, Arribas JR. 2005. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors. J Antimicrob Chemother 55:800-804.
25. Noor MA, Flint OP, Maa JF, Parker RA. 2006. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: Demonstrable differences in vitro and clinically. Aids 20:1813-1821.
26. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
27. Parmer TG, Ward MD, Hait WN. 1997. Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Differ 8:327-334.
28. Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, Hait WN. 1999. Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer 79:59-64.
29. Price NT, Redpath NT, Severinov KV, Campbell DG, Russell JM, Proud CG. 1991. Identification of the phosphorylation sites in elongation factor-2 from rabbit reticulocytes. FEBS Lett 282:253-258.
30. Prot M, Heripret L, Cardot-Leccia N, Perrin C, Aouadi M, Lavrut T, Garraffo R, Dellamonica P, Durant J, Le Marchand-Brustel Y, Binetruy B. 2006. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother 50:3998-4004.
31. Proud CG. 2004. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun 313:429-436.
32. Redpath NT, Price NT, Severinov KV, Proud CG. 1993. Regulation of elongation factor-2 by multisite phosphorylation. Eur J Biochem 213:689-699.
33. Ren H, Tai SK, Khuri F, Chu Z, Mao L. 2005. Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. Cancer Res 65:5841-5847.
34. Riis B, Rattan SI, Clark BF, Merrick WC. 1990. Eukaryotic protein elongation factors. Trends Biochem Sci 15:420-424.
35. Rose AJ, Broholm C, Kiillerich K, Finn SG, Proud CG, Rider MH, Richter EA, Kiens B. 2005. Exercise rapidly increases eukaryotic elongation factor 2 phosphorylation in skeletal muscle of men. J Physiol 569:223-228.
36. Ryazanov AG, Rudkin BB, Spirin AS. 1991. Regulation of protein synthesis at the elongation stage. New insights into the control of gene expression in eukaryotes. FEBS Lett 285:170-175.
37. Sans MD, Xie Q, Williams JA. 2004. Regulation of translation elongation and phosphorylation of eEF2 in rat pancreatic acini. Biochem Biophys Res Commun 319:144-151.
38. Schwarcz SK, Hsu LC, Vittinghoff E, Katz MH. 2000. Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. Am J Epidemiol 152:178-185.
39. Terai K, Hiramoto Y, Masaki M, Sugiyama S, Kuroda T, Hori M, Kawase I, Hirota H. 2005. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol 25:9554-9575.
40. Valerio L, Fontas E, Pradier C, Lavrut T, Garraffo R, Dunais B, Cua E, Dellamonica P. 2005. Lopinavir/ritonavir combination and total/HDL cholesterol ratio. J Infect 50:229-235.
41. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sanchez de la Rosa R, Giralt M, Alvarez ML, Lopez-Dupla M, Torres F, Villarroya F, Cihlar T, Domingo P. 2006. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 50:3824-3832.
42. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ. 2003. Lopinavir: Acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. Aids 17:1092-1094.
43. Wang L, Proud CG. 2002. Regulation of the phosphorylation of elongation factor 2 by MEK-dependent signalling in adult rat cardiomyocytes. FEBS Lett 531:285-289.
44. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. 2001. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20:4370-4379.
45. Yan Q, Hruz PW. 2005. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 40:398-403.